Summit Day One Agenda

7:30 am Registration

8:25 am Chairs Opening Remarks

The Market Perspective

8:30 am Panel Discussion: Exploring the Dermatology Financing Landscape for 2022 & Beyond

Synopsis

  • What are large pharma looking for when partnering & how can smaller biotechs best prepare to partner
  • How & where do you begin with developing a candidate for the rare disease space
  • Debating how to position your drug candidate in the market where patients have failed other trials

9:00 am Development of a Topical Drug Product in the post-pandemic world

9:30 am Where to go Next? Potential Future Treatment Targets in Atopic Dermatitis

  • Patrick Brunner Associate Professor, Icahn School of Medicine Mount Sinai

Synopsis

  • Reviewing the basis for current targets in atopic dermatitis
  • Outlining the most exciting novel targets
  • Pinpointing which promising targets make the most sense to explore

10:00 am Highlighting Opportunities for Novel Drug Development in Hidradenitis Suppurativa

  • Alexandra Charrow Director Hidradenitis Suppurativa & Neutrophilic Dermatosis Clinic, Brigham & Women’s Hospital

Synopsis

  • Categorizing the disease and providing the context around unmet needs
  • Outlining novel targets and cataloging the promising novel drug candidates for the disease
  • Discussing the need for procedural intervention

10:30 am Presentation brought to you by Nordic Bioscience

11:00 am Morning Break & Structured Networking Session

Novel Drug Development & Various Promising Pathways

Track A: IL-4, IL-13 & IL-31 Associated Diseases

Jennifer Gaskin, Senior Director Clinical Operations, Celldex Therapeutics

11:30 am A Novel Approach to Treating Pruritus in Prurigo Nodularis

Synopsis

  • Rationalizing the dual mechanism of action approach as both an antagonist (mu opioid receptor) & agonist (kappa opioid receptor)
  • Providing fresh efficacy data from a phase 3 clinical trial
  • Addressing the challenges with entering the prurigo nodularis market

12:00 pm Spearheading a Novel Compound Targeting the IL-4Ra Cytokine Receptor in Atopic Dermatitis

  • Paul Smith Vice President Discovery Biology, Connect Biopharma

Synopsis

  • Describing the target binding and Th2 cell modulation
  • Clinical responses from a phase 2b clinical trial in atopic dermatitis
  • Future clinical development

12:30 pm Human & Machine: Optimising dermatology clinical trials by AI assisted disease monitoring and quantitative assessment of skin drug effects

Track B: IL17 Associated Diseases, Alopecia & Vitiligo

John Reader, Chief Scientific Officer, Sareum

11:30 am Spearheading a Novel Drug Candidate in Chronic Inflammatory Skin and Joint Diseases

  • Kristian Reich Founder & Chief Scientific Officer, MoonLake Immunotherapeutics

Synopsis

  • Outlining the emerging story of IL-17A and F in inflammatory diseases
  • How to Optimize targeting an important cytokine pathway – MOA and unique molecule characteristics of the novel IL-17 drug candidate sonelokimab
  • Showcasing disease control by sonelokimab from a phase 2b trial in psoriasis
  • Broadening the spectrum – Preparing for success in HS and PsA

12:00 pm How to Approach Vitiligo: A Holistic Overview of the Vitiligo Drug Development Space

  • John Harris Professor and Chair, Department of Dermatology Founding Director, Vitiligo Clinic and Research Center Founding Director, Autoimmune Therapeutics Institute

Synopsis

  • Benchmarking the most promising novel drug candidates in development for the treatment of Vitiligo
  • Incorporating the perspective from the clinic to enhance drug development
  • Exploring the need for increased DEI in the context of Vitiligo

12:30 pm Presentation brought to you by Quantificare

12:50 pm Lunch & Networking

To see more from the agenda, download the full event guide!